AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AgomAb Therapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)
Close on Oct 19, 2026
Community
Notes and questions about AgomAb Therapeutics from other investors
No posts about AGMB yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.